Results 201 to 210 of about 1,677,689 (317)

Impact of CYP3A4 functional variability on ziprasidone metabolism. [PDF]

Front Pharmacol
Zhou Q, Wu Y, Ye Z, Zhang Z, Zheng K, Qian J, Xiao Z, Lu Y.   +7 more
europepmc   +1 more source

The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele‐Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT We investigated the influence of CYP2B6, GSTP1, and SLCO1B1 star allele‐predicted phenotypes and CBR1 variants on clinical outcomes in patients with HCC receiving DOX via TACE. A prospective cohort of patients with HCC underwent DOX therapy via TACE.
Sireen Abdul Rahim Shilbayeh, Omnia A. Abd El‐Baset, Mohammad A. Alshabeeb, Abdalrhman Hamdan Alanizi, Naglaa F. Khedr, Rehab H. Werida   +5 more
wiley   +1 more source

Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the <i>in vivo</i> prediction of individual hepatic clearance. [PDF]

J Gastrointest Oncol
Zhou J, Gao N, Tian X, Fang Y, Gao J, Wen Q, Cui MZ, Zhang YF, Li SF, Jia LJ, Qiao HL.   +10 more
europepmc   +1 more source

Impact of Species and Tissue Differences on In Vitro Glucuronidation of Diclofenac. [PDF]

Molecules
Asare E, Emmanuel S, Du T, Xie H, Liang D, Gao S.   +5 more
europepmc   +1 more source

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

British Journal of Pharmacology, Volume 182, Issue 11, Page 2466-2486, June 2025.
Background and Purpose Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (
Laura Moreno‐Martinez, Núria Gaja‐Capdevila, Laura Mosqueira‐Martín, Mireia Herrando‐Grabulosa, Laura Rodriguez‐Gomez, Klaudia Gonzalez‐Imaz, Ana C. Calvo, Maialen Sagartzazu‐Aizpurua, Leticia Moreno‐García, Jose Manuel Fuentes, Abraham Acevedo‐Arozena, Jesús María Aizpurua, José Ignacio Miranda, Adolfo López de Munain, Ainara Vallejo‐Illarramendi, Xavier Navarro, Rosario Osta, Francisco Javier Gil‐Bea   +17 more
wiley   +1 more source

Evaluation of Violacein Metabolic Stability and Metabolite Identification in Human, Mouse, and Rat Liver Microsomes. [PDF]

Pharmaceutics
Calemi DBA, Godoi AB, Minuti G, Neto FC, Hispagnol GF, Pilon AC, Costa JL, Hyslop S, Antunes NJ.   +8 more
europepmc   +1 more source

Current insights into pathogenesis and anti‐inflammatory treatment strategies for severe alcohol‐associated hepatitis: focus on neutrophil‐targeted therapies

Hepatology Research, Volume 55, Issue 6, Page 785-794, June 2025.
Abstract Alcohol‐associated hepatitis (AH) is the leading cause of liver‐related mortality, with severe alcohol‐associated hepatitis (SAH) showing a short‐term mortality rate of 20%–50% even in developed countries. Corticosteroids are the only evidence‐based pharmacologic treatment, but their efficacy is limited to short‐term survival, with 30%–40% of ...
Ryosuke Kasuga, Po‐Sung Chu, Takanori Kanai, Nobuhiro Nakamoto   +3 more
wiley   +1 more source

Species Differences in the Biotransformation of Aflatoxin B1: Primary Determinants of Relative Carcinogenic Potency in Different Animal Species. [PDF]

Toxins (Basel)
Eaton DL, Williams DE, Coulombe RA.
europepmc   +1 more source

The spatial arrangement of esterases in the microsomal membrane [PDF]

, 1975
Gratzl, Manfred, Nastainczyk, W., Schwab, D.   +2 more
core   +1 more source

Noninvasive Evaluation of Prolonged‐Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial

Liver International, Volume 45, Issue 6, June 2025.
ABSTRACT Background Advanced liver fibrosis (ALF) predicts an adverse prognosis in chronic liver disease. In addition to etiological treatment, a new approach to stop or reverse residual fibrosis is desirable. Objective To assess the efficacy and safety of prolonged‐release pirfenidone (PR‐PFD) versus placebo in compensated cirrhosis.
Linda E. Muñoz‐Espinosa, Aldo Torre, Laura Cisneros, Iaarah Montalvo, René Malé, Scherezada Mejía, Juan Ramón Aguilar, Javier Lizardi, Jaime Zuñiga‐Noriega, María Eugenia Icaza, Frida Gasca‐Díaz, Larissa Hernández‐Hernández, Paula Cordero‐Pérez, Luis Chi, Lilian Torres, Fátima Rodríguez‐Alvarez, Graciela Tapia, Jorge Luis Poo   +17 more
wiley   +1 more source